Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
16.7M
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
359K
-
Shares change
-
-8.34K
-
Total reported value, excl. options
-
$1.44M
-
Value change
-
-$33.7K
-
Number of buys
-
7
-
Number of sells
-
-8
-
Price
-
$4.04
Significant Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) as of Q3 2023
21 filings reported holding VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q3 2023.
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 359K shares
of 16.7M outstanding shares and own 2.16% of the company stock.
Largest 10 shareholders include DSC Advisors, L.P. (115K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (75.8K shares), BlackRock Inc. (44.9K shares), VANGUARD GROUP INC (44.9K shares), GEODE CAPITAL MANAGEMENT, LLC (27.5K shares), RENAISSANCE TECHNOLOGIES LLC (26K shares), STATE STREET CORP (11.7K shares), US BANCORP \DE\ (4.44K shares), BANK OF AMERICA CORP /DE/ (3.42K shares), and Royal Bank of Canada (2.18K shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.